Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-15-1619PMID 26787836PMCID PMC4873448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers

  2014cited by this paper
• New and emerging HDAC inhibitors for cancer treatment.

  2014cited by this paper
• Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment

  2013cited by this paper
• The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression

  2013cited by this paper
• Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease

  2012cited by this paper
• Epigenetics as a Therapeutic Target in Breast Cancer

  2012cited by this paper
• Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells

  2012cited by this paper
• Retinoids, retinoic acid receptors, and cancer.

  2011cited by this paper
• Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

  2011cited by this paper
• SnapShot: retinoic acid signaling.

  2011cited by this paper
• Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

  2010cited by this paper
• Epigenetic modification of retinoic acid-treated human embryonic stem cells.

  2010cited by this paper
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

  2009cited by this paper
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

  2009cited by this paper
• Retinoid signaling regulates breast cancer stem cell differentiation

  2009influential reference
• Regulation of epithelium-specific Ets-like factors ESE-1 and ESE-3 in airway epithelial cells: potential roles in airway inflammation

  2008influential reference
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

  2007cited by this paper
• Molecular definition of breast tumor heterogeneity.

  2007influential reference
• HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acid-induced apoptosis and growth inhibition.

  2007cited by this paper
• ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

  2007cited by this paper
• Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cells.

  2006cited by this paper
• The retinoid anticancer signal: mechanisms of target gene regulation

  2005cited by this paper
• Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.

  2005cited by this paper
• Reconstruction of functionally normal and malignant human breast tissues in mice.

  2004cited by this paper
• Identification of Retinoid-Modulated Proteins in Squamous Carcinoma Cells Using High-Throughput Immunoblotting

  2004cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

  2003cited by this paper
• Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.

  2003cited by this paper
• Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.

  2002cited by this paper
• Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.

  2000cited by this paper
• Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells

  2000cited by this paper
• Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer.

  1999cited by this paper

• CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer

  2026influential citation
• Association of retinoids, retinoic acid receptors and epigenetics in breast cancer.

  2026cites this paper
• Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy

  2025cites this paper
• Exploration The Multifaceted Role Of Vitamins In Epigenetic Regulation: Insights Into DNA Methylation And Histone Modification

  2025cites this paper
• Advancing triple-negative breast cancer therapy: 3D in vitro models to unravel drug resistance mechanisms and tumor microenvironment interactions.

  2025cites this paper
• Cellular and micro-environmental responses influencing the antitumor activity of all-trans retinoic acid in breast cancer

  2024cites this paper
• The function of the ELF3 gene and its mechanism in cancers.

  2024cites this paper
• Journal Pre-proof Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells

  2023cites this paper
• Epithelial-Mesenchymal Transition Axis Lin 28, ARID1A, And ELF3 As A Novel Prognostic Triad in Invasive Ductal Breast Carcinoma

  2023cites this paper
• Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

  2023cites this paper
• Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells

  2023influential citation
• Epigenetics of Thymic Epithelial Tumors

  2023cites this paper
• ERK MAP Kinase Signaling Regulates RAR Signaling to Confer Retinoid Resistance on Breast Cancer Cells

  2022cites this paper
• Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice

  2022cites this paper
• Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor

  2022cites this paper
• Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond

  2022cites this paper
• Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line

  2022cites this paper
• Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way

  2021cites this paper
• Breast cancer stem cells: A review of their characteristics and the agents that affect them

  2021cites this paper
• A New Treatment Strategy for BRCA1-Related Breast Cancer

  2021cites this paper
• CRYβB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer

  2021cites this paper
• 1q21.3 amplification modulates therapy sensitivity in Triple Negative Breast Cancer

  2020cites this paper
• Epigenetic polypharmacology: A new frontier for epi‐drug discovery

  2020cites this paper
• Eradicating the roots: advanced therapeutic approaches targeting breast cancer stem cells.

  2020cites this paper
• Multiple roles of HOX proteins in Metastasis: Let me count the ways

  2020cites this paper
• Multiple roles of HOX proteins in Metastasis: Let me count the ways

  2020cites this paper
• Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis.

  2019cites this paper
• Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells

  2019cites this paper
• Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1.

  2018cites this paper
• The role of the ETS factor ELF3 in the normal and malignant prostate

  2018cites this paper
• Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer

  2018cites this paper
• DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid

  2018cites this paper
• ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer

  2018cites this paper
• Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer

  2018cites this paper
• Histone deacetylase inhibition-mediated neuronal differentiation via the Wnt signaling pathway in human adipose tissue-derived mesenchymal stem cells.

  2018cites this paper
• Robustness and evolvability of heterogeneous cell populations

  2018cites this paper
• Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity

  2018cites this paper
• Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

  2017cites this paper
• Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

  2017cites this paper
• Wnt signaling in triple-negative breast cancer

  2017cites this paper
• Entinostat for the treatment of breast cancer

  2017cites this paper
• Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method

  2017cites this paper
• Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin pathway

  2017cites this paper
• Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors

  2017cites this paper
• Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

  2016cites this paper
• Properties and feasibility of using cancer stem cells in clinical cancer treatment

  2016cites this paper
• Robustness and evolvability of heterogeneous cell populations MBoC

  year unknowncites this paper